Clinical and laboratory investigation of allergy to genetically modified foods. by Bernstein, Jonathan A et al.
Technology has been used for many years to
improve our food supply since the ﬁrst cultiva-
tion of crops such as wheat and barley in
Mesopotamia in 6000 BC and the domestica-
tion of animals such as sheep and goats in
southwestern Asia over 10,000 years ago. More
recently, improvement of our food supply
through genetic manipulation by breeding was
accelerated in the development of hybrid crop
varieties in the 1960s and 1970s (a period
referred to as the green revolution), which
more than doubled the crop production in
developing countries. Breeding and selection
have been used for many domesticated animal
species that are food sources. A good example
is chicken, one of the more expensive meats in
the 1940s, and now one of the least expensive
sources of meat. Cultivation, domestication,
breeding, and selection of certain traits of
plants and animals have created environmental
impacts and major changes to human societies.
Although use of technology in breeding plants
and animals is not new, new methods of
biotechnology incorporate genetic engineering,
also referred to as molecular breeding. Genetic
engineering facilitates the selection, identiﬁca-
tion, and transfer of genes encoding for a spe-
cific protein into the genome of another
organism. This process can determine which
proteins are introduced and where they are
expressed; in most cases, only minute amounts
of a protein need to be expressed to obtain the
desired trait.
In assessing the public health aspects of
genetically engineered foods, it is the proteins
that are expressed that are of interest. Three
possible modes of adverse health effects have
been hypothesized: toxicity, impaired nutri-
tion, and food allergy. Modifications of
expression of protein in foods occur with all
kinds of plant breeding, and these theoretical
concerns are not unique to genetically engi-
neered foods. However, because genetic engi-
neering is a more powerful tool for making
such changes, government authorities in the
United States, Europe, Japan, Canada, and
elsewhere have taken actions to regulate this
class of foods.
In this article, we describe various clinical
aspects of food allergy relevant to the assess-
ment of novel proteins in genetically modiﬁed
foods. Food allergy is among a spectrum of
adverse reactions that can result when an indi-
vidual ingests food or a food additive.
Evaluation of novel proteins for potential
allergenicity is based on a fundamental under-
standing of the clinical and biological aspects
of these responses. Among food allergy
researchers, a number of definitions of food
allergy have been used. For the purpose of this
article, allergy is defined as hypersensitivity
and implies an immunologic reaction to food;
other (nonimmunologic) adverse reactions to
food will be referred to as “intolerance.” This
reﬂects the standard deﬁnitions of terms in the
United States. It is important to note that the
revised nomenclature for allergy proposed by
the European Academy of Allergy and
Clinical Immunology uses the terms “nonal-
lergic food hypersensitivity” instead of “intol-
erance,” and “food allergy” (IgE-mediated or
not) instead of “hypersensitivity.” Deﬁned in
this manner, food allergy affects only those
individuals who have developed an abnormal
immunologic response to food. To under-
stand the public health impacts of food
allergy, we must appreciate both the preva-
lence in the population and the clinical spec-
trum of food allergy.
Although there are a number of clinical
manifestations of food allergy, most of the
focus for clinical evaluation of genetically
modified foods has been on IgE-mediated
anaphylaxis. Various expert committees,
including a committee of the International
Life Sciences Institute, an advisory committee
to the U.S. Environmental Protection Agency
(U.S. EPA), and committees convened by the
Food and Agriculture Organization (FAO)
and the World Health Organization (WHO),
have developed decision trees for identifying
whether novel proteins cause such anaphylac-
tic reactions. These decision trees are largely
based on the clinical and laboratory methods
used to assess the potential allergenicity of
foods. These methods were developed for
clinical purposes but now are being used to
predict allergenicity and for postmarket sur-
veillance. The StarLink corn episode pro-
vided an opportunity for researchers to assess
the utility of the decision tree as well as the
ability to conduct postmarket surveillance for
allergic reactions in foods in commerce. None
of the reported allergic reactions were
conﬁrmed, and it is possible that this episode
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Technology has improved the food supply since the ﬁrst cultivation of crops. Genetic engineering
facilitates the transfer of genes among organisms. Generally, only minute amounts of a specific
protein need to be expressed to obtain the desired trait. Food allergy affects only individuals with
an abnormal immunologic response to food—6% of children and 1.5–2% of adults in the United
States. Not all diseases caused by food allergy are mediated by IgE. A number of expert commit-
tees have advised the U.S. government and international organizations on risk assessment for aller-
genicity of food proteins. These committees have created decision trees largely based on
assessment of IgE-mediated food allergenicity. Difﬁculties include the limited availability of aller-
gen-speciﬁc IgE antisera from allergic persons as validated source material, the utility of speciﬁc
IgE assays, limited characterization of food proteins, cross-reactivity between food and other aller-
gens, and modiﬁcations of food proteins by processing. StarLink was a corn variety modiﬁed to
produce a Bacillus thuringiensis (Bt) endotoxin, Cry9C. The Centers for Disease Control and
Prevention investigated 51 reports of possible adverse reactions to corn that occurred after the
announcement that StarLink, allowed for animal feed, was found in the human food supply.
Allergic reactions were not conﬁrmed, but tools for postmarket assessment were limited. Workers
in agricultural and food preparation facilities have potential inhalation exposure to plant dusts and
ﬂours. In 1999, researchers found that migrant health workers can become sensitized to certain Bt
spore extracts after exposure to Bt spraying. Thus, the potential for occupational and consumer
risks needs to be assessed. Key words: allergens, Bacillus thuringiensis, crops, endotoxins, food
hypersensitivity, genetic engineering, genetics, immunology, recombinant proteins, transgenic
plants. Environ Health Perspect 111:1114–1121 (2003). doi:10.1289/ehp.5811 available via
http://dx.doi.org/ [Online 19 December 2002]
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perceptions about the risks. This episode
demonstrated the limitations of using clinical
tools for assessment of food allergy in post-
market assessment. Another clinical issue is
the potential for development of inhalation
allergy from novel proteins in foods.
Clinical Spectrum of Food
Allergy
H. A. Sampson presented the clinical spectrum
of adverse reactions to food, including food
allergies. Estimates of the prevalence of adverse
food reactions vary widely depending on
whether they are defined using the “gold
standard”—DBPCFC (double-blind placebo-
controlled food challenge)—or as reported
reports by patients and their families. In one
prospective study of children, 6% of children
had food allergy or intolerance conﬁrmed by
DBPCFC, which is lower than the 28%
among children whose parents reported
adverse food reactions (Bock 1987). A number
of prospective studies indicate that allergy to
cow’s milk is prevalent among 2.5% of chil-
dren under the age of 2 years (Bock 1987;
Hide and Guyer 1983; Host et al. 1988;
Schrander et al. 1993), with an overall preva-
lence rate at some time during childhood of
6%. Some children are at greater risk; food
allergy occurs in 30% of children who have
atopic dermatitis (Burks et al. 1988). Food
allergy is less common in adults, affecting
between 1.5 and 2% of adults in the United
States (Jansen et al. 1994; Young et al. 1994).
The development of food allergy most
often occurs in early childhood before the age
of 3 years. It involves mechanisms related to the
nature of the food allergen, the gastrointestinal
tract, and the immune system (Table 1)
(Sampson 1993). Food allergens are proteins,
usually glycoproteins, and they generally share
certain physical and chemical characteristics
(Table 1). Only a few foods are known to cause
the vast majority of allergic reactions: in chil-
dren—eggs, peanuts, milk, soy, and wheat; in
adults—shellﬁsh, ﬁsh, nuts, and peanuts. The
gastrointestinal tract has a number of nonspe-
ciﬁc barriers to the entry of foreign proteins,
and one specific barrier, secretory IgA, pro-
duced by the immune system (Table 1).
Nonetheless, food proteins can be absorbed
into the bloodstream and carried to target
organs. Mechanisms have evolved to ensure
that the immune system does not attack one’s
own proteins (“self”) and proteins in food. The
general process by which the immune system is
programmed not to attack such proteins is
called “tolerance.” Tolerance is therefore a bar-
rier to the development of food allergy, and
when people become sensitized to food, this is a
breakdown of tolerance.
Clinical manifestations. Food allergies are
mediated either by IgE or by other immuno-
logic mechanisms. IgE-mediated reactions are
the most common in the general population.
Non–IgE-mediated food allergies account for
a significant proportion of food allergies in
infants and young children. As shown in
Table 2, food allergy can cause a multitude of
clinical manifestations.
IgE-mediated food allergies. IgE-mediated
food allergies typically develop in an individ-
ual within minutes to hours after ingesting a
food allergen. IgE-mediated food allergies can
have a longer onset in the case of food that has
been ingested more frequently, thus blunting
the immediate symptoms and resulting in
symptoms of a chronic inﬂammatory reaction
that may last for several days. A number of
skin manifestations can occur. On an immedi-
ate basis, acute urticaria/angioedema often
occurs following the ingestion or contact with
a food. Chronic urticaria/angioedema related
to food allergy is rare (Champion et al. 1969;
Volonakis et al. 1992). Children may develop
atopic dermatitis. During blinded food chal-
lenges, an itchy, red, morbilliform (measles-
like) rash develops within 10 to 90 min of
allergen ingestion (Sampson and McCaskill
1985). Repeated ingestion of the allergen may
result in the development of an itchy, eczema-
tous rash (Sampson 1992).
Food allergy can cause both upper and
lower respiratory symptoms (Bock 1992;
James et al. 1994). Recently, James et al.
(1996) established that food allergy can
provoke increased airway hyperreactivity in
food-allergic patients with asthma, and two
studies (Novembre et al. 1988; Oehling and
Baena Cagnani 1980) demonstrated food-
induced wheezing in 6–8% of unselected
asthmatic patients.
Symptoms involving the oropharynx and
gastrointestinal tract may occur within minutes
of ingesting a food allergen. Itching and
swelling of the lips, tongue, and soft palate as
well as nausea, abdominal pain, vomiting, and
diarrhea have all been demonstrated secondary
to food allergy. The oral allergy syndrome con-
sists of symptoms conﬁned exclusively to the
oropharynx and is most commonly reported in
patients with seasonal allergic rhinitis after the
ingestion of one of a variety of fresh fruits and
vegetables (Ortolani et al. 1988; Pastorello et al.
1994). Gastrointestinal anaphylaxis frequently
accompanies symptoms in the skin or respira-
tory tract and presents as nausea, abdominal
cramping, vomiting, and diarrhea. Repeated
ingestion of food allergens in young children
may induce partial desensitization, resulting in
less-obvious symptoms, e.g., gastroesophageal
reflux (GER) instead of projectile vomiting
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Table 1. Mechanisms of the development of food
allergy.
Characteristics
Food allergens Proteins, usually glycoproteins,
generally believed to be 
water soluble, heat resistant,
acid stable, 10–60 kDa 
molecular weight
Gastrointestinal tract Nonspeciﬁc barriers 
Gastric acid and pepsin
Pancreatic and intestinal
enzymes
Mucus secretions
Peristaltic activity
Mucosal epithelial cells
Speciﬁc barrier
Speciﬁc secretory-IgA can
block the absorption 
of foreign proteins
Immune systems Development of immunologic
tolerance
Table 2. Food-allergic illnesses.
Organ system Clinical manifestation
IgE-mediated Skin Urticaria/angioedemaa
Atopic dermatitis
Respiratory Rhinoconjunctivitis
Laryngeal edema
Asthma
Gastrointestinal Nausea and abdominal cramps
Vomiting and diarrhea
Oral allergy syndrome
Infantile colic (rare)
General Anaphylactic shocka
Non–IgE-mediated Skin Dermatitis herpetiformis
Contact dermatitis
Respiratory Heiner’s syndrome
Gastrointestinal Food-induced enterocolitis
Food-induced eosinophilic proctocolitis
Food-induced enteropathy and celiac disease
Allergic eosinophilic gastroenteritis
Gastroesophageal reﬂux
Infantile colic (rare)
aSymptoms also may be provoked by the combination of ingesting speciﬁc food(s) in conjunction with exercising but not
by ingestion of the food alone or exercise alone.
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infantile colic (inconsolable, agonized crying,
drawing up of the legs, abdominal distention,
and excessive gas associated with feeding during
the ﬁrst several months of life) have symptoms
attributed to IgE-mediated food hypersensitivity
(Sampson 1989).
Food-induced systemic anaphylaxis has
been reported to be the leading single cause of
anaphylaxis in emergency departments in the
United States (Kemp et al. 1995; Yocum and
Khan 1994 ). In two reports of fatal anaphylac-
tic reactions (Sampson et al. 1992; Yunginger
et al. 1988), the authors noted that all subjects
had asthma, had unknowingly ingested the
responsible food allergen, and had tended to
minimize the symptoms initially, and that the
initiation of emergency medical management
was delayed. Anaphylactic shock in association
with exercise 2–4 hr after the ingestion of cer-
tain foods is being recognized increasingly,
especially in young women (Horan and Sheffer
1991; Romano et al. 1995).
Non–IgE-mediated allergic reactions.
Non–IgE-mediated allergic reactions are
believed to take several hours to days to
develop, and a variety of disorders have been
delineated. A variety of gastrointestinal dis-
orders believed to have an immunologic basis
have been described. Food-induced enterocolitis
syndrome is seen most frequently in young
infants ingesting cow’s milk- or soy-based for-
mulas. It generally presents between 1 week
and 3 months of age, with protracted diarrhea
and projectile vomiting often severe enough to
produce dehydration (Powell 1978). The syn-
drome also is seen in exclusively breast-fed
infants (secondary to the passage of food pro-
teins in maternal milk) and occasionally in
older children (associated with ingestion of
egg, wheat, rice, peanut, nuts, chicken, turkey,
and shellfish). Benign eosinophilic procto-
colitis, also present in the first few weeks to
months of life, is often secondary to cow’s milk
or soy, although about half the infants are
being exclusively breast-fed (Machida et al.
1994; Odze et al. 1995). Patients appear clini-
cally well and present only with bloody stools
(gross or occult) or hematochezia. Lesions are
confined to the distal bowel and vary from
mucosal edema to ulceration and linear ero-
sions. Both enterocolitis and proctocolitis show
dramatic clinical resolution within 72 hr of
allergen elimination.
Food protein–induced enteropathy includes
a spectrum of malabsorption disorders that
generally present with protracted diarrhea,
vomiting in up to two-thirds of patients, fail-
ure to thrive, and carbohydrate malabsorption.
Increased fecal fat and abnormal D-xylose
absorption generally are present. Cow’s milk
sensitivity is the most frequent cause of this
syndrome, but it also has been associated
with soy, egg, wheat, rice, chicken, and fish
hypersensitivity. Patchy villous atrophy with
cellular inﬁltrate on biopsy is characteristic of
this disorder (Kuitunen et al. 1975; Nagata et
al. 1995). A more extensive enteropathy, with
total villous atrophy and extensive cellular
inﬁltrate (celiac disease), is associated with sen-
sitivity to gliadin, a component of gluten.
These patients often present with diarrhea or
frank steatorrhea, abdominal distention and
ﬂatulence, weight loss, and occasionally nausea
and vomiting.
Dermatitis herpetiformis is a highly itchy
skin rash (sometimes mistaken for atopic der-
matitis) associated with gluten-sensitive
enteropathy (Hall 1987). Biopsy of the skin
rash reveals an infiltration of polymorpho-
nuclear leukocytes and deposits of IgA at the
dermal-epidermal junction. Administration of
dapsone or other sulfones often relieves the skin
itching within 24 hr. Like celiac disease, elimi-
nation of all gluten for 3–4 months may be
required to normalize intestinal biopsy ﬁndings.
Allergic eosinophilic gastroenteritis (AEG)
may involve food allergy (Min 1991), as may
infantile colic. AEG often presents as post-
prandial nausea with vomiting, abdominal
pain, diarrhea, occasionally steatorrhea, and
weight loss in the adult, or failure to thrive in
the infant (Lee et al. 1993). In the mucosal
form, patients often have atopic disease, ele-
vated serum IgE levels, positive immediate
skin tests to a variety of foods and aeroaller-
gens, peripheral eosinophilia, iron deﬁciency
anemia, and hypoalbuminemia. Protein-
losing enteropathy or pyloric obstruction may
be the main feature in some infants with AEG
(Snyder et al. 1987; Waldman et al. 1967).
A recent study of 10 patients with AEG
and severe GER found that non–IgE-mediated
food allergy may be a much more common
cause of AEG than previously appreciated
(Kelly et al. 1995). Food hypersensitivity is a
frequent cause of GER in young infants. Milk
allergy was the cause of GER in 85 of 204
(42%) of infants less than 1 year of age (Iacono
et al. 1996). Removal of the suspect allergen
for up to 12 weeks may be required to bring
about resolution of symptoms and intestinal
histologic changes.
Natural history of food allergy. Experience
and follow-up challenge studies on food-allergic
individuals indicate that food allergies are not
necessarily lifelong. Studies have demonstrated
the loss of food allergy in up to one-third of
children (Sampson and Scanlon 1989) in 1–3
years of age, even though results of skin tests
and radioallergosorbent assays (RASTs) may
not change. Evidence suggests that the likeli-
hood of losing a food allergy is dependent upon
the food provoking the symptoms and the
degree to which the patient maintains the aller-
gen elimination diet. Allergy to peanut, tree
nuts, ﬁsh, and other seafood appears to be more
long-lasting (Sampson and Scanlon 1989).
Diagnosis. Many subjective complaints
have been ascribed to adverse food reactions,
including neurologic (dizziness, weakness,
headaches, numbness, loss of concentration,
depression), gastrointestinal (generalized
bloating, abdominal distention, constipation),
musculoskeletal (muscle cramps, myalgia,
arthralgia, vasculitis), and miscellaneous com-
plaints (sweating, chest pain, fatigue, itchy
earlobes) (National Research Council 2000b).
Such symptoms can rarely, if ever, be con-
ﬁrmed with blinded food challenges.
Evaluation of a patient for suspected ad-
verse food reactions involves a thorough his-
tory, physical examination, and laboratory tests.
With the history, an attempt is made to estab-
lish whether the patient is suffering from an
intolerance or hypersensitivity reaction, and if
the latter, whether a non–IgE- or IgE-mediated
mechanism is involved. If an IgE-mediated
food hypersensitivity is suspected, the clinical
impression may be reinforced by performing
prick skin tests or in vitro diagnostic tests.
Skin testing with food extracts by the prick
or puncture method may be helpful. Routine
intradermal skin tests with food extracts are too
sensitive and nonspeciﬁc (leading to excessive
false-positive tests), carry a higher risk of provok-
ing systemic reactions, and are not indicated. A
positive skin test denotes the presence of aller-
gen-speciﬁc IgE antibodies bound to cutaneous
mast cells; it does not mean the patient will
develop symptoms when ingesting the speciﬁc
food. In fact, the positive predictive values of
most prick skin tests are less than 50%. In con-
trast, the negative predictive accuracies are excel-
lent, and IgE-mediated allergic reactions are
extremely rare in the face of negative skin tests.
In vitro tests of food-speciﬁc IgE antibodies
are often used in patients with extensive skin
disease, significant and prolonged der-
matographism, or a history of exquisite sensi-
tivity (i.e., exposure to minute quantities of a
speciﬁc food resulted in a life-threatening reac-
tion). A newer test, the CAP system FEIA (ﬂu-
orescent-enzyme immunoassay; Pharmacia
Diagnostics, Uppsala, Sweden) quantitates the
amount of food-speciﬁc IgE antibodies, which
correlates better with clinical reactivity.
Elimination diets are used when the history
and/or preliminary laboratory studies suggest
certain foods may be provoking a patient’s
symptoms. Foods (and all hidden sources of
that food) suspected of inducing symptoms are
totally eliminated from the patient’s diet for
1–2 weeks. If symptoms appear to improve,
further characterization of the sensitivity
should be pursued (e.g., endoscopy and biopsy,
blinded challenge, and so forth). In several
chronic disorders (e.g., atopic dermatitis,
asthma, or chronic diarrhea), factors in addi-
tion to the food hypersensitivity may be
triggering symptoms, so that failure to see reso-
lution of symptoms during the elimination
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hypersensitivity. In cases where food hypersen-
sitivity or intolerance are suspected but no spe-
cific foods can be incriminated, a brief trial
(i.e., 2–4 weeks) of an oligoantigenic or ele-
mental diet may be helpful. If patient symp-
toms persist unabated, it is very unlikely that
food is a contributing factor.
In the practice setting, open or single-
blind oral food challenges may be used to
screen for food allergic reactions. However, in
cases where multiple food allergies are diag-
nosed, positive responses should be conﬁrmed
by DBPCFCs. DBPCFCs have been used suc-
cessfully in both children and adults for exam-
ining a variety of food-related complaints. The
choice of foods used in DBPCFCs is based on
history, skin test RAST results, and/or foods
suspected on the basis of elimination diets.
The diagnosis of food allergy is a clinical
exercise that requires a careful history, selective
skin tests or RASTs in cases of suspected IgE-
mediated disorders, appropriate exclusion
diets, and blinded provocation challenges.
Currently, there is no evidence of diagnostic
utility for the following assays: quantitation of
food-speciﬁc IgG or IgG4 antibodies or food
antigen-antibody complexes, evidence of lym-
phocyte activation (3H uptake, interleukin-2
production, leukocyte inhibitory factor pro-
duction, etc.), or sublingual or intracutaneous
provocation. In gastrointestinal disorders
where pre- and postchallenge biopsy studies
are required for diagnosis (e.g., malabsorption
syndromes, including celiac disease), the chal-
lenge does not require blinding.
Assessment of Allergenicity to
Genetically Modiﬁed Foods
and Novel Proteins
S. Lehrer recounted the efforts undertaken to
assess the potential allergenicity of genetically
modified foods. Recently, the U.S. National
Academy of Sciences and other national science
academies reviewed the issue of genetically
modiﬁed foods. The report cited good reasons
for the development of the science of agricul-
tural biotechnology. The potential to alter the
food supply suggests the possiblity of develop-
ing less-expensive and healthier foods that
could play a role in the elimination of defi-
ciency diseases and aid in feeding the growing
world population. There is also the potential to
reduce chemical pesticide use and increase the
productivity of land, thus protecting habitat for
other species (National Research Council
2000b). Another panel of the National
Academy of Sciences looked specifically at
plants genetically modiﬁed to include pesticidal
properties. This panel concluded that there was
no evidence that the technology is unsafe. At
the same time, the committee conveyed con-
cerns with ecologic risks of gene spread from
the genetically modiﬁed crop to wild relatives
and the development of pesticide-resistant
superweeds. They also have cited a number of
theoretical health concerns, including changes
in nutritional composition or availability of
nutrients in food, production of toxins, and
potential of developing more allergenic foods or
novel allergens in new foods (National Research
Council 2000a).
Allergenicity risk assessment for genetically
modiﬁed foods. During the last 5 years, a num-
ber of national groups, governmental agencies,
and industry organizations, as well as interna-
tional organizations such as the FAO of the
United Nations and WHO, have become inter-
ested in issues of allergy and allergenicity assess-
ment of these new food products. These
organizations have supported a number of
meetings and reports in which allergy risk
assessment for genetically modiﬁed foods was
addressed. The potential alteration of allergens
in foods concerned changes in endogenous pro-
tein levels, expression of known allergens in dif-
ferent foods, and the expression of novel
proteins that may be allergenic. The U.S. Food
and Drug Administration (U.S. FDA) held one
of the earliest meetings (in 1994) to address
these issues (Metcalfe et al. 1996). Following
this meeting, a series of meetings held by differ-
ent organizations resulted in an evolving deci-
sion-tree process that continues to be altered
according to new information about allergen
structure and activity. The most recent version
of such a decision tree came out of a WHO
workshop in 2001 and is shown in Figure 1
(FAO/WHO 2001).
At this time, decision processes for aller-
genicity assessment make the initial choice of
study on the basis of the source of the gene, that
is, whether it is from a known allergen source
or an unknown allergen source (Figure 1). If
the gene is from a known allergen source, solid-
phase immunoassays can be used to determine
whether a known allergen is expressed in the
new product. This information can be used to
make a judgment about the potential for aller-
genicity of the product and whether it should
be produced. Conversely, if the protein is from
an unknown allergenic source or a source with
little human exposure information, the ability
to assess the potential for allergenicity is more
problematic. On the basis of their physical and
chemical properties, it is possible to identify
novel proteins with little resemblance to known
allergens and to judge that such proteins would
have a lower likelihood of allergenicity.
However, the predictive value of such an assess-
ment is unknown. As mentioned in a previous
paper in this mini-monograph (Metcalfe 2003),
amino acid sequence comparison with known
allergens, particularly known allergenic epi-
topes, has also been considered. This is in the
original decision tree presented by Metcalfe
et al. in 1996 (Metcalfe et al. 1996).
The practice of allergy risk assessment for
genetically modiﬁed foods and novel proteins
has generally worked well but should be
improved as our knowledge of food allergy
increases. Although stability in processing and
enzymatic digestion is useful, assessments are
not well standardized and validated. Amino
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FAO/WHO 2001 Decision Tree
Assessment of the allergenic potential of foods
derived from biotechnology FAO/WHO 2001
Source of gene
Allergenic Yes No
Sequence homology
Specific serum screen Targeted serum screen
Pepsin resistance and
animal models
+/+
High
–/+     –/–
Low
Probability of allergenicity
Likely allergenic
Sequence homology
Yes No
Yes
No
Yes
Yes
No
No
Figure 1. Decision-tree approach to determining the potential allergenicity of novel food products.acid sequence similarity, as mentioned earlier,
is being used more frequently, particularly as
more allergens are sequenced. However,
major questions concerning the comparison
remain. Should it be the whole molecule or
parts of the molecule? If parts of the mole-
cule, should it be epitopes? What percent
identity is important? All of these issues need
to be resolved, and obtaining more informa-
tion on allergen protein structure in particular
will help make this process more precise.
A validated animal model would aid greatly
in the assessment process. Such a model should
respond to known food allergens in a manner
similar to the human. One would expect that
allergenic foods would have much more signiﬁ-
cant IgE reactivity than nonallergenic foods in
such an animal model; allergenic proteins
within the allergenic foods would have the
same reactivity; and a pattern of reactivity to
epitopes similar to that seen in man would be
demonstrated in the animal. 
The amount of food required for allergic
sensitization or provocation in man is not
known. This could provide important infor-
mation, particularly if there is a level below
that at which an allergen is not a risk. Several
groups are addressing this process and should
yield important information. Finally, more
importance needs to be placed on the structure
and sequence comparison, not only with aller-
gens but also with nonallergens. If a novel pro-
tein with no background of allergenicity is very
similar in structure and function to a nonaller-
gen, should this not be an important lesson?
StarLink corn, produced by Aventis
Corporation (Bridgewater Crossing, NJ) was
approved by the U.S. EPA as a pesticide when
produced for sale as an animal feed. In
September 2000, it was reported and con-
firmed that StarLink had contaminated the
human food supply. The basis for the
approval process of StarLink only for animals
was that it contained Cry9c, a protein from
Bacillus thuringiensis (Bt), that appeared to be
heat stable when compared with other Bt pro-
teins and thus could not be excluded as an
allergen (because allergenicity could not be
ruled out), using an earlier version of the deci-
sion tree (Bucchini and Goldman 2002).
Because of the importance of this exposure,
the U.S. FDA, the U.S. EPA, and the U.S.
Department of Agriculture Food Safety and
Inspection Service asked the National Food
Processors Association (NFPA) to provide assis-
tance in obtaining member company informa-
tion related to potential adverse events that
could conceivably be related to StarLink corn in
processed foods. Eleven food companies sub-
mitted data to the NFPA on consumer contacts
associated with processed foods containing yel-
low corn and possibly StarLink. Additional
information estimating production units, total
consumer contacts, allergy health contacts, and
allergy-related product recalls was also pro-
vided. The U.S. Centers for Disease Control
and Prevention (CDC) selected four time peri-
ods for review: 1998, when 10,000 acres of
StarLink corn were planted; 1999, when
250,000 acres of StarLink corn were planted;
and the year 2000 up to 17 September, when
350,000 acres of StarLink corn were planted.
The fourth period was from 18 September
through 11 November 2004, a 2-month period
in which numerous product recalls ensued
related to StarLink and thousands of media
reports were issued.
The NFPA studies found no correlation
between the amount of exposure to StarLink
corn and the allergy/health contacts or allergy
complaints to corn products. There appears to
be a positive association between the number
of allergy/health contacts for processed food
containing yellow corn and the intense media
coverage of StarLink-related product recalls.
Clinical and Laboratory
Methods in the Assessment 
of the Allergenicity of Foods
R.G. Hamilton reviewed the methods for
assessing food allergy. Any decision tree is
only as good as the clinical and laboratory
methods used in the assessment of the aller-
genicity of foods. The objective of this pre-
sentation was to discuss each component
of the International Food Biotechnology
Consortium (IFBC)/Allergy and Immunology
Institute - International Life Sciences Institute
(ILSI)/FAO/WHO Decision Tree (FAO/
WHO 2001), with an emphasis on laboratory
and clinical methods useful for investigating
potential allergenicity of proteins in geneti-
cally modiﬁed foods.
Allergenicity has been deﬁned as the ability
to induce IgE antibodies that react with a pro-
tein (immunogenicity) or that cross-react with
structurally similar epitopes. Allergenicity is
determined by the antigenicity or foreignness of
a molecule (size and stability), the extent of
allergen exposure (allergen concentration), and
the genetic predisposition of a host for inducing
an allergic response (Hamilton 2001).
The IFBC/ILSI report estimates that
approximately 160 foods and food-related sub-
stances are associated with allergic reactions
(Metcalfe 1996). As of December 2001, 98
foods speciﬁcities have been U.S. FDA-cleared
for IgE antibody measurement, and an addi-
tional 95 food speciﬁcities are in an allergen-
speciﬁc reagent status for human IgE antibody
testing with the Pharmacia CAP System.
The ﬁrst level of the allergenicity assessment
framework involves an examination of sequence
homology to known allergens. What do we
know about the predictive value of sequence
homology? The primary structures of amino
acid sequences deduced from cDNA are usu-
ally not complete because of posttranslational
modiﬁcations (e.g., glycosylation of asparagines,
serines, threonines; hydroxylation of prolines,
lysines). Is the database of allergen amino acid
sequences comprehensive? Aalberse and Stapel
(2001) identiﬁed four structural families among
40 allergenic food proteins via 3D protein fold
representations in 2D proximity plots. They
concluded that allergens have no characteristic
structural features other than they need to reach
(and stimulate) immune cells and mast cells.
Within this constraint, any antigen may be
allergenic, particularly if it avoids activation of
T-helper (Th)-2 suppressive mechanisms
(CD8, Th1 cells).
Establishing serological assays for the
detection of allergen-specific IgE antibody
involves the use of a number of reagents
(Hamilton 1997; Hamilton and Sobotka
2000). The ﬁrst is a source of human IgE anti-
body. Pools of sera from well-characterized
patients are needed, as IgE antibody levels are
low (in the nanograms per milliliter range).
The process of preparing serum pools dilutes
out IgE antibodies with minor allergen speci-
ficities, so the process favors major allergen
specificities. Such dilution is important, as
biotechnology or other plant breeding meth-
ods theoretically can increase the expression of
minor allergens, which would not be detected
in such serum pools.
The second group of reagents needed for
serological assays is a validated allergen source
prepared by extracting the plant or food in a
clearly deﬁned manner with regard to extrac-
tion buffer, time, temperature, agitation, ﬁltra-
tion, dialysis, and concentration (Hamilton
and Sobotka 2000). This creates obvious chal-
lenges. Plant/food extraction conditions may
vary widely, and such variability can increase
the chance that cross-reactivity may occur.
Cross-reactivity occurs when a protein other
than the allergen source binds to the allergen-
speciﬁc IgE. Cross-reactivity may or may not
be of clinical significance. Pastorello et al.
(2000) reported an experiment in which crude
extracts of corn showed signiﬁcant cross-reac-
tivity with peach, which was not found with
the puriﬁed corn protein. Such cross-reactivity
can confuse the assessment of allergenicity.
Clinically, several U.S. FDA–cleared
immunoassays are available for detecting aller-
gen-specific IgE antibody in serum. These
include the CAP System (Pharmacia),
AlaSTAT (Diagnostic Products Corp., Los
Angeles, CA), and Hy-TECH (Hycor,
Garden Grove, CA). These clinical assays use
a total serum IgE heterologous reference curve
traceable to WHO IgE standard and quantita-
tive IgE antibody results reported in kilo-
international units per liter. There are also a
number of research immunoassays that are less
well characterized, including RAST, ELISA,
and the immunoenzymetric assay (IEMA).
Research IEMA assays that employ the native
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in detecting IgE antibodies specific for these
proteins (Hamilton 1997, 2001; Hamilton
and Sobotka 2000).
The clinical utility of assays for measuring
food-specific IgE antibodies in serum is
another important issue. A clinical diagnosis
requires conﬁrmation of clinical reactivity in
vivo. Using DBPCFC, Sampson (2001) con-
ducted a prospective study of children and
adolescents and established 95% predictive
decision points for egg-, milk-, peanut-, and
ﬁsh-speciﬁc IgE antibody, as measured in the
Pharmacia CAP System.
All of this is predicated on the notion that
a food is a well-defined package of proteins
and other constituents that can be easily char-
acterized. However, we know that this is not
the case. The experience with latex allergy in
the United States illustrates the complexity of
allergens in plant products. After universal
precautions were instituted in 1986, there
began an epidemic of allergic reactions and
deaths associated with sensitization to a num-
ber of proteins in natural rubber products
derived from latex of the Hevea brasiliensis
tree (Hev b 1-Hev b 13). Use and exposure to
latex in medical gloves was one major risk fac-
tor for latex allergen sensitization; sensitiza-
tion was documented among 7% of health
care workers and up to 50% of children with
spina bifida. Cross-reactivity between latex
proteins and certain food allergens was one of
the factors that helped to identify latex-aller-
gic individuals. Some of the common foods
with deﬁned cross-reactivity to latex are avo-
cado, banana, chestnut, kiwi, raw potato,
tomato, stone fruits (e.g., peach, cherry),
hazelnut, melons, celery, carrot, apple, pear,
papaya, and almond. Foods with less well-
defined cross-reactivity to latex are peanut,
peppers, citrus fruits, coconut, pineapple,
mango, ﬁg, passion fruit, ugli fruit, and grape
(Salcedo et al. 2001).
From the latex experience, evidence has
emerged for a family of proteinous plant pan-
allergens, proteins that include profilin,
patatin, plant stress proteins (WIN 1 and 2),
and Bet v 1 and Bet v 2 (birch [Betula verru-
cosa] proteins). At present, thirteen allergenic
Hevea proteins have been identified (cloned
and sequenced) from latex, and these serve a
variety of functions in the rubber tree. These
proteins have quite different structures and
molecular sizes. Breiteneder and Ebner devel-
oped a list of protein types among known
food allergens (Breiteneder and Ebner 2000):
a) pathogenesis-related proteins involved
with defense against pests; b) seed-storage
proteins; c) alpha amylase/protease inhibitors
(wheat/barley/rye);  d) Kunitz trypsin
inhibitors (inhibit growth of larvae); e) thiol
proteases (e.g., papain-papaya, ficin-fig, Gly
m 1 soybean); f ) profilins (12–15 kd actin
cytoskeleton-binding protein, Ara h 5
peanut, Gly m 3 soybean, Hev b 8 latex; g)
peroxidases (induced by pathogens in plant
defense); and h) lectins (agglutinins that bind
specific sugars on glycoproteins: 31 kDa
peanut). It is evident that there will be no
easy way to identify novel food allergens
based on functional attributes of each pro-
tein. In addition, it is clear that some of the
functional attributes of food allergens are
those that may be the most desirable to plant
breeders, for example, increasing the plant
resistance to pests. Hanninen et al. observed
in one experiment on turnips that plant stress
can increase the concentrations of certain
allergenic proteins (Hanninen et al. 1999).
Can food processing increase the concentra-
tions of allergenic proteins? One observation
is that South American latex-allergic children
with spina biﬁda routinely eat bananas with-
out any apparent allergy problems. In con-
trast, latex-sensitized children (and adults) in
North America often experience allergic reac-
tions after eating bananas. In the United
States, food distribution centers treat unripe
bananas and other produce with ethylene to
ripen; this is not commonly done in South
America. Does treatment of food with ethyl-
ene induce banana proteins that cross-react
with latex? Some research indicates that this
can be the case for certain foods (Sanchez-
Monge et al. 2000). Although we currently
do not know the magnitude of this problem,
it does illustrate another source of variability
in the allergenicity of foods.
Can Postmarketing
Surveillance Provide Useful
Information about the
Allergenicity of Genetically
Modiﬁed Foods? The StarLink
Corn Experience
C. Rubin outlined the situation with respect
to postmarket surveillance for allergy to
genetically modified foods. When a person
manifesting signs or symptoms (e.g., hives,
facial swelling, difﬁculty breathing) consistent
with acute allergic reaction to a food product
seeks medical care, the treatment is usually
symptomatic, the episode is often isolated,
and the potential allergen is seldom identiﬁed.
The number of such medical visits is not tab-
ulated. Even repeat visits for allergic reactions
to well-known allergens such as peanuts or
milk are not counted as part of any estab-
lished surveillance system. Thus, in October
2000, when StarLink corn intended only for
animal consumption was identified in prod-
ucts on grocery-store shelves, there was no
way to easily determine if consumption of
this genetically engineered protein was result-
ing in allergic reactions in humans (Bucchini
and Goldman 2002).
In a coordinated effort to determine if
StarLink corn was indeed responsible for
adverse human health effects, the U.S. FDA
and the CDC used existing postmarket sur-
veillance resources to follow up people who
self-identiﬁed as experiencing allergic reactions
(CDC 2001). After media reports about
StarLink, individuals in 18 states and territo-
ries called the U.S. FDA to report health
effects potentially related to ingesting a corn
product. Fifty-one people reported signs and
symptoms that varied from gastrointestinal ill-
ness to anaphylactic shock. These reports were
entered into the adverse events reporting sys-
tem (AERS) that the U.S. FDA has used since
1997 to passively collect information about
adverse human health effects related to the use
of drugs marketed in the United States. Self-
or physician-reports to AERS regarding food-
related illness generate a standardized form
that chronicles food consumption history,
details the timing and manifestations of the
adverse health event, and describes any med-
ical treatment. The U.S. FDA aggregated all
of the AERS reports received between 1 July
and 30 November 2000 that mentioned con-
sumption of a corn product. With all personal
identiﬁers removed, these reports were sent to
CDC for review to determine the likelihood
that any of the reports were potentially related
to StarLink.
CDC developed a case definition that
included a) a suspected anaphylactic reaction
(e.g., dizziness, weakness, or loss of conscious-
ness) that occurred within 1 hr of product
consumption; or b) any of the following der-
matological or oropharyngeal symptoms
(hives, rash, pruritus, oropharyngeal tingling
or swelling) that occurred within 12 hr of
product consumption; or c) any of the follow-
ing gastrointestinal symptoms (vomiting,
diarrhea, abdominal cramping) that occurred
within 12 hr of product consumption and
that involved only one individual among meal
companions. It was also necessary that these
symptoms were not explained by a preexisting
medical condition.
Twenty-eight of the 51 reports were con-
sistent with the case definition. The U.S.
FDA then contacted each potential case
person and requested permission for CDC to
follow up the adverse health event. Each
potential case was administered a detailed
questionnaire, gave consent to obtain medical
records, and was also asked to contribute a
serum sample that would be stored until a test
could be developed to measure IgE antibodies
to Cry9c protein. Although all 28 people
appeared to have clinically experienced an
immediate hypersensitivity to an allergen, our
postmarketing surveillance could not demon-
strate that the Cry9c protein was actually in
the product consumed prior to the adverse
health event. A serological test for antibodies
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speciﬁc to acute hypersensitivity was consid-
ered to be the safest way to evaluate whether
any of these people were indeed sensitive to
the genetically modiﬁed protein in StarLink.
The U.S. FDA developed an ELISA test that
found no IgE antibody reactivity to Cry9c in
any of the serum samples. This test was lim-
ited because the Cry9c used in the ELISA was
a recombinant protein produced in bacteria
rather than the protein expressed in plants.
Concern that this difference may alter the
protein’s allergenicity has encouraged
researchers to work on developing additional
tests to further demonstrate the lack of reac-
tivity to the Cry9c protein. This work is in
progress, and the results will be published in
the near future.
The StarLink experience demonstrates
many of the limitations in using postmarket
surveillance for adverse reactions to food as a
method for assessing allergenicity to a protein
that has been newly introduced into the food
supply. Intensive epidemiologic investigation
and laboratory test development by federal
investigators was not sufficient to determine
whether individual allergic reactions were asso-
ciated with the inadvertent release of a geneti-
cally modified protein into the human food
supply. It is also unlikely that postmarketing
physicians or hospital-based surveillance
would have been able to detect any increase in
allergic reactions during the time that StarLink
corn was available to consumers. The symp-
toms described in the case deﬁnition used in
this investigation are generic and could have
been attributed to a variety of etiologies. The
StarLink example demonstrates many of the
problems with any surveillance system that tries
to capture rare and somewhat generic health
events such as food allergy.
Is Susceptibility to Food
Allergy in Workers Sensitized
by Inhalant Exposure to 
B. thuringiensis kurstaki a
Relevant Model for Sensitivity
to Genetically Modiﬁed Foods?
L. Bernstein reviewed the occupational allergy
experience with inhalation of Bt proteins.
Novel proteins in genetically modified food
may be present in the dust in workplaces
where such foods are processed or handled.
Novel proteins in genetically modified food
may be present in the dust in workplaces
where such foods are processed or handled.
Thus, occupational populations may be
exposed via inhalation. The possibilities of
prior exposure and allergic sensitization to
proteins that are potentially cross-reactive
with novel proteins contained in genetically
modiﬁed foods should be considered relevant
risk factors prior to general introduction of
such foods into the human food chain. By
serendipity, this hypothetical circumstance
actually occurred before StarLink corn was
inadvertently discovered in food products
generally available to human consumers.
In 1999, researchers discovered that mi-
grant health workers developed positive skin
tests and elevated specific IgE and IgG anti-
body levels to B. thuringiensis kurstaki (Btk)
spore extracts containing Cry1Aa and
Cry1Ab delta endotoxin proteins after respi-
ratory exposure to Btk crop spraying
(Bernstein et al. 1999). A number of positive
skin tests, as well as increased levels of speciﬁc
IgE and IgG antibodies, were present in more
highly exposed groups than in medium- to
low-exposure groups. Preexisting atopy was
also a risk factor for workers with positive
skin and serologic tests in the medium- and
low-exposure groups. Although consumers
frequently use Btk spray products for garden-
ing purposes, similar risk assessment studies
in this population have not been investigated.
Because of the documented success of Btk
delta endotoxin insecticides in the control of
corn borer larvae, investigators postulated that
direct incorporation of genes encoding these
proteins into corn and maize seeds would fur-
ther enhance productivity of these commodi-
ties. Cry1Aa and Cry1Ab genes were among
the ﬁrst Btk genes to be used for this purpose.
Later, the Cry9C gene, uniquely modiﬁed to
enable persistence of the encoded protein in
the larval gut, was used in StarLink transgenic
corn seed. Although immunologic cross-reac-
tivity between Cry1A and Cry9C proteins has
not yet been investigated, it is of particular
interest that these proteins share proteomic
homology in 75% of their conserved amino
acid residues as well as identity of the chief
domains that determine tertiary structure of
these proteins.
For the above reasons and in view of prior
experience with respiratory occupational expo-
sure to Btk in migrant workers, researchers
extensively reviewed the literature concerning
the occurrence of subsequent food allergy in
workers previously sensitized after respiratory
exposure to a variety of food proteins (Cartier
et al. 1984; Leser et al. 2001; Lybarger et al.
1982; Smith et al. 1987). Unfortunately, there
were a limited number of cross-sectional stud-
ies of occupational asthma (OA) induced by
inhaled food proteins where the question of
subsequent food allergy was addressed.
However, in plants processing foods such as
eggs, snow crabs, and condiments, 18 (35%)
of 51 workers with conﬁrmed OA developed
food allergy symptoms at varying intervals
after the onset of OA (Table 3).
A future approach to the potential aller-
genicity of genetically modiﬁed foods during
postmarketing surveillance should include
human susceptibility and risk factors in atopic
subset populations; prior occupational expo-
sure and sensitization to related proteins; and
prior consumer exposure and sensitization to
related proteins.
Occupational exposure to novel proteins
and potential sensitization is an issue that has
had little study, yet could be of public health
signiﬁcance. Approaches are available for fur-
ther study, and exposed cohorts are available.
Conclusions
The introduction of genetically modiﬁed foods
into the marketplace has brought to light the
challenges inherent in identification of food
allergens and individuals who are sensitive to
those allergens. Although theoretically any
plant-breeding technique can modify (increase
or decrease) the allergenicity of foods, biotech-
nology has a greater potential to introduce
novel proteins into the food supply, and thus
has been subjected to closer scrutiny by regula-
tors. Expert bodies have developed a decision
tree for assessment of food allergy risks from
such foods. All aspects of current food allergy
assessments, both clinical and laboratory tools,
have technical challenges that must be
addressed if such tools are brought into a regu-
latory context. However, our challenge scientif-
ically is how to assess novel proteins that have
little or no exposure in the general population
and thus no readily available tools for the pre-
diction of exposures. The experiences with
StarLink corn and in occupational cohorts
exposed to grain dusts suggest that the devel-
opment of methods to be used for postmarket
consumer and occupational health surveillance
may be useful. Thus, the current FAO/WHO
decision tree for assessment of food allergy
risks may require revision to include evalua-
tion of appropriate diagnostic tests in these
susceptible population groups, and to address
technical challenges in assessing proteins
newly introduced into the diet. Later papers in
this monograph suggest research strategies for
development of tools that may be useful for
the prediction and/or postmarket surveillance
of allergy to novel proteins in foods.
Table 3. Prevalence of food allergy to foods that induce occupational asthma by inhalation.
Suspected OA Conﬁrmed OA Food allergy
Allergen (n)( n)( n) Reference
Egg 29 8 4 Smith et al. 1987; Leser et al. 2001
Snow crab 103 37 12 Cartier et al. 1984
Garlic 3 3 1 Lybarger et al. 1982
Condiments 3 3 1 Bernstein et al. Unpublished observations
Total 138 51 18 (35%)
Mini-Monograph | Bernstein et al.Environmental Health Perspectives • VOLUME 111 | NUMBER 8 | June 2003 1121
REFERENCES
Aalberse RC, Stapel SO. 2001. Structure of food allergens in
relation to allergenicity. Pediatr Allergy Immunol 12:10–14.
Bernstein IL, Bernstein JA, Miller M, Tierzieva S, Bernstein DI,
Lummus Z, et al. 1999. Immune responses in farm workers
after exposure to Bacillus thuringiensis pesticides.
Environ Health Perspect 107:575–582.
Bock SA. 1987. Prospective appraisal of complaints of adverse
reactions to foods in children during the first 3 years of
life. Pediatrics 79:683–688.
———. 1992. Respiratory reactions induced by food chal-
lenges in children with pulmonary disease. Pediatr Allergy
Immunol 3:188–194.
Breiteneder H, Ebner C. 2000. Molecular and biochemical clas-
sification of plant-derived food allergens. J Allergy Clin
Immunol 106:27–36.
Bucchini L, Goldman LR. 2002. Starlink corn: a risk analysis.
Environ Health Perspect 110:5–13.
Burks AW, Mallory SB, Williams LW, Shirrell MA. 1988. Atopic
dermatitis: clinical relevance of food hypersensitivity reac-
tions. J Pediatr 113:447–451.
Cartier A, Malo JL, Forest F, Lafrance M, Pineau L, St-Aubin JJ,
et al. 1984. Occupational asthma in snow crab-processing
workers. J Allergy Clin Immunol 74:261–269.
CDC. 2001. Investigation of Human Health Effects Associated
with Potential Exposure to Genetically Modified Corn: A
Report to the U.S. Food and Drug Administration from the
Centers for Disease Control and Prevention. Atlanta,
GA:Centers for Disease Control and Prevention.
Champion RH, Roberts SO, Carpenter RG, Roger JH. 1969.
Urticaria and angio-oedema. A review of 554 patients. Br J
Dermatol 81:588–597.
FAO/WHO. 2001. Evaluation of Allergenicity of Genetically
Modified Foods. Report of a Joint FAO/WHO Expert
Consultation of Allergenicity of Foods Derived from
Biotechnology. Available: http://www.fao.org/es/esn/gm/
allergygm.pdf [accessed 11 September 2002].
Hall RP. 1987. The pathogenesis of dermatitis herpetiformis:
recent advances. J Am Acad Dermatol 16:1129–1144.
Hamilton RG. 1997. Immunological tests for the diagnosis and
management of human allergic disease: total and allergen-
speciﬁc IgE and allergen-speciﬁc IgG. In: Manual of Clinical
Laboratory Immunology (Rose HR, de Macario EC, Fahey JL,
Friedman H, Penn GM, eds). Washington, DC:American
Society for Microbiology, 881.
———. 2001. Assessment of allergic diseases. In: Clinical
Immunology (Rich RR, Fleisher TA, Shearer WT, Schroeder
HW, Kotzin B, eds). 2nd ed. London:Harcourt Health
Sciences, 124.1–124.14.
Hamilton RG, Sobotka AK. 2000. In vitro diagnostic tests of IgE-
mediated reactions. In: Diagnostic Testing of Allergic
Diseases (Kemp SF, Lockey RF, eds). New York:Marcel
Dekker, 89–110.
Hanninen AR, Mikkola JH, Kalkkinen N, Turjanmaa K, Ylitalo L,
Reunala T, et al. 1999. Increased allergen production in
turnip (Brassica rapa) by treatments activating defense
mechanisms. J Allergy Clin Immunol 104:194–201.
Hide DW, Guyer BM. 1983. Cows milk intolerance in Isle of
Wight infants. Br J Clin Pract 37:285–287.
Horan R, Sheffer A. 1991. Food-dependent exercise-induced
anaphylaxis. Immunol Allergy Clin North Am 11:757–766.
Host A, Husby S, Osterballe O. 1988. A prospective study of
cow’s milk allergy in exclusively breast-fed infants.
Incidence, pathogenetic role of early inadvertent exposure
to cow’s milk formula, and characterization of bovine milk
protein in human milk. Acta Paediatr Scand 77:663–670.
Iacono G, Carroccio A, Cavataio F, Montalto G, Kazmierska I,
Lorello D, et al. 1996. Gastroesophageal reflux and cow’s
milk allergy in infants: a prospective study. J Allergy Clin
Immunol 97:822–827.
James JM, Bernhisel-Broadbent J, Sampson HA. 1994.
Respiratory reactions provoked by double-blind food chal-
lenges in children. Am J Respir Crit Care Med 149:59–64.
James JM, Eigenmann PA, Eggleston PA, Sampson HA. 1996.
Airway reactivity changes in asthmatic patients undergo-
ing blinded food challenges. Am J Respir Crit Care Med
153:597–603.
Jansen JJ, Kardinaal AF, Huijbers G, Vlieg-Boerstra BJ, Martens
BP, Ockhuizen T. 1994. Prevalence of food allergy and intol-
erance in the adult Dutch population. J Allergy Clin Immunol
93:446–456.
Kelly KJ, Lazenby AJ, Rowe PC, Yardley JH, Perman JA,
Sampson HA. 1995. Eosinophilic esophagitis attributed to
gastroesophageal reflux: improvement with an amino
acid-based formula. Gastroenterology 109:1503–1512.
Kemp SF, Lockey RF, Wolf BL, Lieberman P. 1995. Anaphylaxis.
A review of 266 cases. Arch Intern Med 155:1749–1754.
Kuitunen P, Visakorpi JK, Savilahti E, Pelkonen P. 1975.
Malabsorption syndrome with cow’s milk intolerance.
Clinical findings and course in 54 cases. Arch Dis Child
50:351–356.
Lee CM, Changchien CS, Chen PC, Lin DY, Sheen IS, Wang CS, et
al. 1993. Eosinophilic gastroenteritis: 10 years experience.
Am J Gastroenterol 88:70–74.
Leser C, Hartmann AL, Praml G, Wuthrich B. 2001. The “egg-
egg” syndrome: occupational respiratory allergy to airborne
egg proteins with consecutive ingestive egg allergy in the
bakery and confectionery industry. J Invest Allergol Clin
Immunol 11:89–93.
Lybarger JA, Gallagher JS, Pulver DW, Litwin A, Brooks S,
Bernstein IL. 1982. Occupational asthma induced by
inhalation and ingestion of garlic. J Allergy Clin Immunol
69:448–454.
Machida HM, Catto Smith AG, Gall DG, Trevenen C, Scott RB.
1994. Allergic colitis in infancy: clinical and pathologic
aspects. J Pediatr Gastroenterol Nutr 19:22–26.
Metcalfe DD. 2003. Introduction: what are the issues in address-
ing the allergenic potential of genetically modiﬁed foods?
Environ Health Perspect 111:1110–1113.
Metcalfe DD, Astwood JD, Townsend R, Sampson HA, Taylor SL,
Fuchs RL. 1996. Assessment of the allergenic potential of
foods derived from genetically engineered crop plants. Crit
Rev Food Sci Nutr 36:S165–S186.
Min KU. 1991. Eosinophilic gastroenteritis. Immunol Allergy Clin
North Am 11:799–813.
Nagata S, Yamashiro Y, Ohtsuka Y, Shioya T, Oguchi S, Shimizu
T, et al. 1995. Quantitative analysis and immunohistochem-
ical studies on small intestinal mucosa of food-sensitive
enteropathy. J Pediatr Gastroenterol Nutr 20:44–48.
National Research Council. 2000a. Genetically Modified Pest-
Protected Plants: Science and Regulation. Washington,
DC:National Academy Press.
———. 2000b. Transgenic Plants and Worldwide Agriculture.
Washington, DC:National Academy Press.
Novembre E, de Martino M, Vierucci A. 1988. Foods and respi-
ratory allergy. J Allergy Clin Immunol 81:1059–1065.
Odze RD, Wershil BK, Leichtner AM, Antonioli DA. 1995. Allergic
colitis in infants. J Pediatr 126:163-170.
Oehling A, Baena Cagnani CE. 1980. Food allergy and child
asthma. Allergol Immunopathol (Madr) 8:7–14.
Ortolani C, Ispano M, Pastorello E, Bigi A, Ansaloni R. 1988. The
oral allergy syndrome. Ann Allergy 61:47–52.
Pastorello EA, Farioli L, Pravettoni V, Ispano M, Scibola E,
Trambaioli C, et al. 2000. The maize major allergen, which is
responsible for food-induced allergic reactions, is a lipid
transfer protein. J Allergy Clin Immunol 106:744–751.
Pastorello EA, Ortolani C, Farioli L, Pravettoni V, Ispano M, Borga
A, et al. 1994. Allergenic cross-reactivity among peach,
apricot, plum, and cherry in patients with oral allergy syn-
drome: an in vivo and in vitro study. J Allergy Clin Immunol
94:699–707.
Powell GK. 1978. Milk- and soy-induced enterocolitis of infancy.
Clinical features and standardization of challenge. J Pediatr
93:553–560.
Romano A, Di Fonso M, Giuffreda F, Quaratino D, Papa G,
Palmieri V, et al. 1995. Diagnostic work-up for food-depen-
dent, exercise-induced anaphylaxis. Allergy 50:817–824.
Salcedo G, Diaz-Perales A, Sanchez-Monge R. 2001. The role of
plant panallergens in sensitization to natural rubber latex.
Curr Opin Allergy Clin Immunol 1:177–183.
Sampson H. 1993. Adverse reactions to foods. In: Allergy:
Principles and Practice (Middleton E, Reed CE, Elliset EF,
eds). 4th ed. St. Louis:C.V. Mosby Co., 1661–1686.
Sampson HA. 1989. Infantile colic and food allergy: fact or ﬁc-
tion? J Pediatr 115:583–584.
———. 1992. The immunopathogenic role of food hypersen-
sitivity in atopic dermatitis. Acta Derm Venereol Suppl
176:34–37.
———. 2001. Utility of food-speciﬁc IgE concentrations in pre-
dicting symptomatic food allergy. J Allergy Clin Immunol
107:891–896.
Sampson HA, McCaskill CC. 1985. Food hypersensitivity and
atopic dermatitis: evaluation of 113 patients. J Pediatr
107:669–675.
Sampson HA, Mendelson L, Rosen JP. 1992. Fatal and near-fatal
anaphylactic reactions to food in children and adolescents.
N Engl J Med 327:380–384.
Sampson HA, Scanlon SM. 1989. Natural history of food hyper-
sensitivity in children with atopic dermatitis. J Pediatr
115:23–27.
Sanchez-Monge R, Blanco C, Perales AD, Collada C, Carrillo T,
Aragoncillo C, et al. 2000. Class I chitinases, the panaller-
gens responsible for the latex-fruit syndrome, are induced
by ethylene treatment and inactivated by heating. J Allergy
Clin Immunol 106:190–195.
Schrander JJ, van den Bogart JP, Forget PP, Schrander-
Stumpel CT, Kuijten RH, Kester AD. 1993. Cow’s milk protein
intolerance in infants under 1 year of age: a prospective
epidemiological study. Eur J Pediatr 152:640–644.
Smith AB, Bernstein DI, Aw TC, Gallagher JS, London M, Kopp S,
et al. 1987. Occupational asthma from inhaled egg protein.
Am J Ind Med 12:205–218.
Snyder JD, Rosenblum N, Wershil B, Goldman H, Winter HS.
1987. Pyloric stenosis and eosinophilic gastroenteritis in
infants. J Pediatr Gastroenterol Nutr 6:543–547.
Volonakis M, Katsarou-Katsari A, Stratigos J. 1992. Etiologic fac-
tors in childhood chronic urticaria. Ann Allergy 69:61–65.
Waldman T, Wochner R, Laster R, Gordon RS. 1967. Allergic
gastroenteropathy: a cause of excessive gastrointestinal
protein loss. N Engl J Med 276:761–769.
Yocum MW, Khan DA. 1994. Assessment of patients who have
experienced anaphylaxis: a 3-year survey. Mayo Clin Proc
69:16–23.
Young E, Stoneham MD, Petruckevitch A, Barton J, Rona R.
1994. A population study of food intolerance. Lancet
343:1127–1130.
Yunginger JW, Sweeney KG, Sturner WQ, Giannandrea LA,
Teigland JD, Bray M, et al. 1988. Fatal food-induced ana-
phylaxis. JAMA 260:1450–1452.
Mini-Monograph | Clinical aspects of food allergy